|
1）Unwin N, Gan D, Whiting D. The IDF Diabetes Atlas: providing evidence, raising awareness and promoting action. Diabetes Res Clin Pract. 2010; 87: 2-3
|
|
|
|
2）Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979; 241: 2035-8
|
|
|
|
|
|
3）Kannel WB, McGee DL. Diabetes and glucose tolerance as risk factors for cardiovascular disease: the Framingham study. Diabetes Care. 1979; 2: 120-6
|
|
|
|
|
|
4）Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The solvd investigators. N Engl J Med. 1991; 325: 293-302
|
|
|
|
|
|
5）Prevention CfDCa. National diabetes fact sheet: National esti-mates and general information on diabetes and prediabetes in the united states, 2011. Atlanta, GA, USA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2011
|
|
|
|
|
|
6）Yancy CW, Fowler MB, Colucci WS, et al. Group USCHFS. Race and the response to adrenergic blockade with carvedilol in patients with chronic heart failure. N Engl J Med. 2001; 344: 1358-65
|
|
|
|
|
|
7）Cohn JN, Tognoni G. Valsartan Heart Failure Trial I. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-75
|
|
|
|
|
|
8）Rubler S, Dlugash J, Yuceoglu YZ et al. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972; 30: 595-602
|
|
|
|
|
|
9）Bando YK, Murohara T. Diabetes-related heart failure. Circ J. 2014; 78: 576-83
|
|
|
|
|
10）Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147-239
|
|
|
|
|
|
11）Authors/Task Force Members, Ryden L, Grant PJ, Anker SD, et al. Esc Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology （EAC） and developed in collaboration with the European Association for the Study of Diabetes （EASD）. Eur Heart J. 2013; 34: 3035-87
|
|
|
|
|
|
12）Bell DS. Diabetic cardiomyopathy. Diabetes Care. 2003; 26: 2949-51
|
|
|
|
|
|
13）Cheung N, Wang JJ, Rogers SL, et al. Diabetic retinopathy and risk of heart failure. J Am Coll Cardiol. 2008; 51: 1573-8
|
|
|
|
|
|
14）Scognamiglio R, Negut C, De Kreutzenberg SV, et al. Postprandial myocardial perfusion in healthy subjects and in type 2 diabetic patients. Circulation. 2005; 112: 179-84
|
|
|
|
|
|
15）Bugger H, Abel ED. Molecular mechanisms for myocardial mitochondrial dysfunction in the metabolic syndrome. Clin Sci. 2008; 114: 195-210
|
|
|
|
|
|
16）Shigeta T, Aoyama M, Bando YK, et al. Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions. Circulation. 2012; 126: 1838-51
|
|
|
|
|
|
17）dos Santos L, Salles TA, Arruda-Junior DF, et al. Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. Circ Heart Fail. 2013; 6: 1029-38
|
|
|
|
|
|
18）Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014; 114: 1788-803
|
|
|
|
|
|
19）Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013; 17: 819-37
|
|
|
|
|
|
20）Vasekar M, Craig TJ. ACE inhibitor-induced angioedema. Curr Allergy Asthma Rep. 2012; 12: 72-8
|
|
|
|
|
|
21）Byrd JB, Adam A, Brown NJ. Angiotensin-converting enzyme inhibitor-associated angioedema. Immunol Allergy Clin North Am. 2006; 26: 725-37
|
|
|
|
|
|
22）Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003; 40: 209-94
|
|
|
|
|
|
23）Shen XZ, Bernstein KE. The peptide network regulated by angiotensin converting enzyme （ACE） in hematopoiesis. Cell Cycle. 2011; 10: 1363-9
|
|
|
|
|
|
24）Lefebvre J, Murphey LJ, Hartert TV, et al. Dipeptidyl peptidase IV activity in patients with ACE-inhibitor-associated angioedema. Hypertension. 2002; 39: 460-4
|
|
|
|
|
|
25）Byrd JB, Touzin K, Sile S, et al. Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema. Hypertension. 2008; 51: 141-7
|
|
|
|
|
|
26）Brown NJ, Byiers S, Carr D, et al. Dipeptidyl peptidase-IV inhibitor use associated with increased risk of ACE inhibitor-associated angioedema. Hypertension. 2009; 54: 516-23
|
|
|
|
|
|
27）White WB, Cannon CP, Heller SR, et al; EXAMINE Investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013; 369: 1327-35
|
|
|
|
|
|
28）Scirica BM, Bhatt DL, Braunwald E, et al; SAVOR-TIMI 53 Streering Committee and Investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013; 369: 1317-26
|
|
|
|
|